Marketresearch.biz reports that the The global Personalized Medicine Biomarkers Market was valued at USD 15.5 Billion in 2022. It is expected to reach USD 67.6 Billion by 2032, with a CAGR of 16.3% during the forecast period from 2023 to 2032.Overview of the Personalized Medicine Biomarkers MarketThe Personalized Me.
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) CEO Paul J. Diaz sold 57,844 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $25.13, for a total transaction of $1,453,619.72. Following the transaction, the chief executive officer now directly owns 1,236,166 shares of […]
Myriad Genetics, Inc. (NASDAQ:MYGN) Director Lee Nisley Newcomer Sells 6,200 Shares of Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 Myriad Genetics, Inc. , a.
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Leerink Partnrs themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.